Bevacizumab as adjuvant for neovascular glaucoma

Acta Ophthalmologica

Volumn 88, Issue 1, 2010, Pages 103-109

  Beutel, Julia ^a   Peters, Swaantje ^a   Lüke, Matthias ^a   Aisenbrey, Sabin ^b   Szurman, Peter ^b   Spitzer, Martin S ^b   Yoeruek, Efdal ^b   Grisanti, Salvatore ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bevacizumab; Iris rubeosis; Ischaemic retinopathy; Neovascular glaucoma; VEGF

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANTERIOR EYE CHAMBER ANGLE; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DRUG EFFECT; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; LASER COAGULATION; LONG TERM CARE; MALE; NEOVASCULAR GLAUCOMA; PRIORITY JOURNAL; RETINA ISCHEMIA; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; CRYOSURGERY; DIABETIC RETINOPATHY; EYE; EYEGLASSES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; IRIS DISEASES; ISCHEMIA; LIGHT COAGULATION; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETINAL DETACHMENT; RETINAL VEIN OCCLUSION; RETINAL VESSELS; RETROSPECTIVE STUDIES; VISUAL ACUITY; VITRECTOMY;

EID: 76149113572     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01355.x     Document Type: Article

References (16)

1. Avery RL (2006 Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 : 352 354.
2. Central Vein Occlusion Study Group (1995 A randomized clinical trial of early panretinal photocoagulation for ischaemic central vein occlusion. Ophthalmology 102 : 1434 1444.
3. Davidorf FH, Mouser JG Derick RJ (2006 Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26 : 354 356.
4. Diabetic Retinopathy Study Research Group (1978 Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmology 85 : 82 106.
5. Eggleston TF, Bohling CA, Eggleston HC Hershey FB (1980 Photocoagulation for ocular ischaemia associated with carotid artery occlusion. Ann Ophthalmol 12 : 84 87.
6. Ehrenberg M, McCuen BW II., Schindler RH Machemer R (1984 Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology 91 : 321 325.
7. Ferrara N, Hillan KJ, Gerber HP Novotny W (2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 : 391 400.
8. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU Tübingen Bevacizumab Study Group (2006 Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142 : 158 160.
9. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S Sarra GM (2006 Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 142 : 1054 1066.
10. Kahook MY, Schuman JS Noecker RJ (2006 Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 37 : 144 146.
11. Kernt M, Neubauer AS Kampik A (2007 Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85 : 119 120. (Pubitemid 46140172)
12. Mason JO III., Albert MA Jr., Mays A Vail R (2006 Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26 : 839 841.
13. ®) in proliferative diabetic retinopathy. Acta Ophthalmol Scand [Epub ahead of print].
14. Shima C, Sakaguchi H, Gomi F et al. (2008 Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86 : 372 376.
15. Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L Scott IU (2006 Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84 : 556 557.
16. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU Jorge R (2008 Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi Study). Acta Ophthalmol 86 : 385 389.